Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Author:
Publisher
Elsevier BV
Subject
Gastroenterology,Hepatology
Reference112 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma;Mazzaferro;Gastroenterology,2018
3. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial;Bruix;Lancet Oncol,2015
4. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update;Reig;J Hepatol,2022
5. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Polypeptides-Based Nanocarriers in Tumor Therapy;Pharmaceutics;2024-09-10
2. Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study;Frontiers in Immunology;2024-09-03
3. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma;Cancer Communications;2024-09-02
4. Heating up the immune battle: Magnetic hyperthermia against cancer;Fundamental Research;2024-09
5. Similar usage of T‐cell receptor β‐chain between tumor and adjacent normal tissue in hepatocellular carcinoma;Cancer Medicine;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3